Remy Sukhija - Madrigal Pharmaceuticals VP Officer
| MDGL Stock | USD 331.45 5.29 1.57% |
Insider
Remy Sukhija is VP Officer of Madrigal Pharmaceuticals
| Age | 52 |
| Address | Four Tower Bridge, West Conshohocken, PA, United States, 19428 |
| Phone | 267 824 2827 |
| Web | https://www.madrigalpharma.com |
Madrigal Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5225) % which means that it has lost $0.5225 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2976) %, meaning that it created substantial loss on money invested by shareholders. Madrigal Pharmaceuticals' management efficiency ratios could be used to measure how well Madrigal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.61. The value of Return On Capital Employed is expected to slide to -0.77. At this time, Madrigal Pharmaceuticals' Total Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 3.3 M this year, although the value of Non Currrent Assets Other will most likely fall to about 719.9 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| MSc MBA | Inozyme Pharma | 52 | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| David Tice | Arcellx | 53 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Rik Derynck | Pliant Therapeutics | N/A | |
| Ellen Welch | PTC Therapeutics | N/A | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
| Christopher MD | Arcellx | 44 | |
| Mike Ouimette | Pliant Therapeutics | 51 | |
| David Glynn | Krystal Biotech | N/A | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Alexandra HughesWilson | Mereo BioPharma Group | 53 | |
| ric MD | Pliant Therapeutics | 60 | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| Narinderjeet MS | Arcellx | 52 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Dean MD | Pliant Therapeutics | N/A | |
| Friedrich MD | Iovance Biotherapeutics | 57 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Demetrios MD | Inozyme Pharma | N/A | |
Management Performance
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.52 |
Madrigal Pharmaceuticals Leadership Team
Elected by the shareholders, the Madrigal Pharmaceuticals' board of directors comprises two types of representatives: Madrigal Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Madrigal. The board's role is to monitor Madrigal Pharmaceuticals' management team and ensure that shareholders' interests are well served. Madrigal Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Madrigal Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Hare, Senior Management | ||
| Remy Sukhija, VP Officer | ||
| Mardi Dier, Principal CFO | ||
| Justin Drinkwine, Senior VP | ||
| PharmD MBA, Senior Affairs | ||
| Mark Underwood, Senior Operations | ||
| William Sibold, President CEO | ||
| Ronald Filippo, Chief Officer | ||
| Rebecca MD, Chief Founder | ||
| Robert Waltermire, Chief Officer | ||
| Carole Huntsman, Chief Officer | ||
| Paul MD, Chairman CEO | ||
| Edward Chiang, Senior Operations | ||
| Clint Wallace, Chief Officer | ||
| Tina Ventura, Chief Officer | ||
| Kianoush Motesharei, Senior Development | ||
| Shannon Kelley, Chief Officer | ||
| Alex Howarth, Executive Officer | ||
| Brian JD, Senior Counsel |
Madrigal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Madrigal Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (1.87) % | ||||
| Current Valuation | 6.35 B | ||||
| Shares Outstanding | 21.81 M | ||||
| Shares Owned By Insiders | 8.56 % | ||||
| Shares Owned By Institutions | 91.44 % | ||||
| Number Of Shares Shorted | 4.43 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 9.30 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.